William E. Rote

Insider Reports History

Entity
Individual
Location
C/O Retrophin, Inc., 3721 Valley Centre Drive, Suite 200, San Diego, CA
Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by William E. Rote:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Travere Therapeutics, Inc. SENIOR VICE PRESIDENT, R&D Common Stock 84.5K $973K $11.52 Sep 9, 2024 Direct
Travere Therapeutics, Inc. SENIOR VICE PRESIDENT, R&D Employee stock option (right to buy) 65K Jan 31, 2024 Direct

Insider Reports Filed by William E. Rote

Symbol Company Period Transactions Value $ Form Type Date Filed Role
TVTX Travere Therapeutics, Inc. Sep 5, 2024 2 -$50.5K 4 Sep 9, 2024 SENIOR VICE PRESIDENT, R&D
TVTX Travere Therapeutics, Inc. Jan 31, 2024 4 -$41.5K 4 Feb 2, 2024 SENIOR VICE PRESIDENT, R&D
TVTX Travere Therapeutics, Inc. Jan 23, 2024 1 -$18.5K 4 Jan 25, 2024 SENIOR VICE PRESIDENT, R&D
TVTX Travere Therapeutics, Inc. Aug 31, 2023 2 -$26.7K 4 Sep 5, 2023 Senior Vice President, R&D
TVTX Travere Therapeutics, Inc. May 10, 2023 1 -$13.7K 4 May 12, 2023 Senior Vice President, R&D
TVTX Travere Therapeutics, Inc. Jan 31, 2023 4 -$57.6K 4 Feb 2, 2023 Senior Vice President, R&D
TVTX Travere Therapeutics, Inc. Jan 24, 2023 1 -$44.3K 4 Jan 26, 2023 Senior Vice President, R&D
TVTX Travere Therapeutics, Inc. May 11, 2022 2 -$33.9K 4 May 12, 2022 Senior Vice President, R&D
TVTX Travere Therapeutics, Inc. Jan 31, 2022 5 -$30.8K 4 Feb 2, 2022 Senior Vice President, R&D
TVTX Travere Therapeutics, Inc. Jan 24, 2022 1 -$46.8K 4 Jan 26, 2022 Senior Vice President, R&D
TVTX Travere Therapeutics, Inc. Jan 10, 2022 2 -$68.5K 4 Jan 12, 2022 Senior Vice President, R&D
TVTX Travere Therapeutics, Inc. Aug 13, 2021 2 -$24.1K 4 Aug 17, 2021 Senior Vice President, R&D
TVTX Travere Therapeutics, Inc. May 11, 2021 2 -$60.3K 4 May 13, 2021 Senior Vice President, R&D